Skip Navigation



Annals of Oncology Advance Access published online on November 12, 2007
Annals of Oncology, doi:10.1093/annonc/mdm521
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/4/814    most recent
mdm521v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rodríguez-Galindo, C.
Right arrow Articles by Krasin, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodríguez-Galindo, C.
Right arrow Articles by Krasin, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

Prognostic factors for local and distant control in Ewing sarcoma family of tumors

C. Rodríguez-Galindo1,*, F. Navid1, T. Liu2, C. A. Billups2, B. N. Rao4 and M. J. Krasin3

1 Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
2 Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN, USA
3 Department of Radiological Sciences, St Jude Children's Research Hospital, Memphis, TN, USA
4 Department of Surgery, St Jude Children's Research Hospital, Memphis, TN, USA

* Correspondence to: Dr C. Rodríguez-Galindo, Department of Oncology, St Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA. Tel: +1-901-495-2203; Fax: +1-901-521-9005; E-mail: carlos.rodriguez-galindo{at}stjude.org

Background: Advances in the treatment of Ewing sarcoma family of tumors (ESFT) are the result of improvements in systemic and local therapies. The individual contributions of each treatment component cannot be analyzed separately; improvements in local and systemic control can influence each other.

Patients and methods: We reviewed the records of 220 patients treated on institutional protocols from 1979 to 2004. Factors predictive of local and distant recurrence were analyzed.

Results: The median age at diagnosis was 13.7 years. Ninety-five patients relapsed at a median of 1.6 years. The 5-year overall survival estimate was 63.5% ± 3.5%. The estimated 5-year cumulative incidence (CI) of local failure was 25.1% ± 3.0%. Local failure was associated with treatment era (P < 0.001), tumor size (P = 0.037) and type of local control (P = 0.021). Systemic treatment intensification improved local control. The estimated 5-year CI of distant recurrence was 22.5% ± 2.9%. Patients with localized disease (P < 0.001), smaller tumors (P = 0.018) and those who received surgery ± radiation for local control (P = 0.023) had lower CI of distant failure.

Conclusions: Successful treatment of ESFT requires optimal systemic and local therapy. Both treatment modalities are intertwined and the control of both local and distant disease is the result of the combined approach.

distant recurrence, Ewing sarcoma, local recurrence, pediatric cancer

Received for publication May 27, 2007. Revision received October 8, 2007. Accepted for publication October 9, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.